secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001437749-25-038213
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences receives FDA IDE approval to initiate NANOPULSE-AF clinical study for paroxysmal atrial fibrillation
--------------------------------------------------------------------------------

- FDA approved IDE for Pulse Biosciences' nPulse Cardiac Catheter System to treat paroxysmal atrial fibrillation in NANOPULSE-AF study.
- Study is single-arm, multicenter, prospective; up to 30 sites (3 outside US) and up to 145 patients planned.
- Ongoing European feasibility study has enrolled 150 patients; positive initial outcomes support device's potential.
- nPulse uses nanosecond PFA aiming for complete circumferential lesion in single energy application without stacking.
- CEO Paul LaViolette calls FDA approval a major milestone; follow-up data expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925038213/0001437749-25-038213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925038213/plse20251218_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-038213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer